We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.80 | -1.21% | 65.14 | 65.13 | 65.14 | 65.60 | 64.89 | 65.62 | 3,315,646 | 20:03:20 |
From Oct 2023 to Apr 2024
By Colin Kellaher
Shares of Arcellx jumped more than 10% in premarket trading Wednesday after the clinical-stage biotechnology company inked an extension of its collaboration with Gilead Sciences that includes a $200 million equity investment at a rich premium.
Gilead, which late last year invested $100 million for a nearly 7.2% stake in Arcellx, is buying an additional 3.24 million share at $61.68 each, 30% above Tuesday's closing price of $47.47 and nearly triple Arcellx's closing price of $21.68 on Dec. 8, 2022, the day before the companies unveiled their collaboration.
The new investment will raise Gilead's stake in Arcellx to around 13%, making it the Gaithersburg, Md., company's largest shareholder, according to FactSet data.
Arcellx shares were recently up 12% to $53.26 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 15, 2023 08:15 ET (13:15 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
